We can’t show the full text here under this license. Use the link below to read it at the source.
Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus
Effects of glucagon-like peptide 1 drugs on other health problems in older adults with diabetes
AI simplified
Abstract
Elderly patients with diabetes are at high risk of polypharmacy, which increases the likelihood of adverse drug events.
- Polypharmacy is prevalent among elderly patients with diabetes due to multiple coexisting diseases and syndromes.
- Cognitive and sensory deficits in these patients may hinder timely reporting of adverse drug events.
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may help reduce the number of medications needed for managing diabetes and its comorbidities.
- GLP-1 RAs have multiple effects on conditions commonly associated with diabetes, such as hyperlipidemia, hypertension, and fatty liver.
- Using GLP-1 RAs could potentially lower costs, decrease medication burden, and improve adherence among older patients.
AI simplified